130 related articles for article (PubMed ID: 16759855)
1. 1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors.
Dinges J; Ashworth KL; Akritopoulou-Zanze I; Arnold LD; Baumeister SA; Bousquet PF; Cunha GA; Davidsen SK; Djuric SW; Gracias VJ; Michaelides MR; Rafferty P; Sowin TJ; Stewart KD; Xia Z; Zhang HQ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4266-71. PubMed ID: 16759855
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
Akritopoulou-Zanze I; Albert DH; Bousquet PF; Cunha GA; Harris CM; Moskey M; Dinges J; Stewart KD; Sowin TJ
Bioorg Med Chem Lett; 2007 Jun; 17(11):3136-40. PubMed ID: 17391959
[TBL] [Abstract][Full Text] [Related]
3. Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors.
Dinges J; Akritopoulou-Zanze I; Arnold LD; Barlozzari T; Bousquet PF; Cunha GA; Ericsson AM; Iwasaki N; Michaelides MR; Ogawa N; Phelan KM; Rafferty P; Sowin TJ; Stewart KD; Tokuyama R; Xia Z; Zhang HQ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4371-5. PubMed ID: 16750628
[TBL] [Abstract][Full Text] [Related]
4. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
5. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347
[TBL] [Abstract][Full Text] [Related]
6. Scaffold oriented synthesis. Part 1: Design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors.
Akritopoulou-Zanze I; Darczak D; Sarris K; Phelan KM; Huth JR; Song D; Johnson EF; Jia Y; Djuric SW
Bioorg Med Chem Lett; 2006 Jan; 16(1):96-9. PubMed ID: 16216502
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors.
El-Deeb IM; Park BS; Jung SJ; Yoo KH; Oh CH; Cho SJ; Han DK; Lee JY; Lee SH
Bioorg Med Chem Lett; 2009 Oct; 19(19):5622-6. PubMed ID: 19700314
[TBL] [Abstract][Full Text] [Related]
9. Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.
Kopecky DJ; Hao X; Chen Y; Fu J; Jiao X; Jaen JC; Cardozo MG; Liu J; Wang Z; Walker NP; Wesche H; Li S; Farrelly E; Xiao SH; Kayser F
Bioorg Med Chem Lett; 2008 Dec; 18(24):6352-6. PubMed ID: 18993068
[TBL] [Abstract][Full Text] [Related]
10. Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors.
Orvieto F; Branca D; Giomini C; Jones P; Koch U; Ontoria JM; Palumbi MC; Rowley M; Toniatti C; Muraglia E
Bioorg Med Chem Lett; 2009 Aug; 19(15):4196-200. PubMed ID: 19541484
[TBL] [Abstract][Full Text] [Related]
11. Lead optimisation of pyrazoles as novel FPR1 antagonists.
Morley AD; King S; Roberts B; Lever S; Teobald B; Fisher A; Cook T; Parker B; Wenlock M; Phillips C; Grime K
Bioorg Med Chem Lett; 2012 Jan; 22(1):532-6. PubMed ID: 22094028
[TBL] [Abstract][Full Text] [Related]
12. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
[TBL] [Abstract][Full Text] [Related]
13. Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.
Burchat A; Borhani DW; Calderwood DJ; Hirst GC; Li B; Stachlewitz RF
Bioorg Med Chem Lett; 2006 Jan; 16(1):118-22. PubMed ID: 16216497
[TBL] [Abstract][Full Text] [Related]
14. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.
Snow RJ; Abeywardane A; Campbell S; Lord J; Kashem MA; Khine HH; King J; Kowalski JA; Pullen SS; Roma T; Roth GP; Sarko CR; Wilson NS; Winters MP; Wolak JP; Cywin CL
Bioorg Med Chem Lett; 2007 Jul; 17(13):3660-5. PubMed ID: 17499505
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
Fucini RV; Hanan EJ; Romanowski MJ; Elling RA; Lew W; Barr KJ; Zhu J; Yoburn JC; Liu Y; Fahr BT; Fan J; Lu Y; Pham P; Choong IC; VanderPorten EC; Bui M; Purkey HE; Evanchik MJ; Yang W
Bioorg Med Chem Lett; 2008 Oct; 18(20):5648-52. PubMed ID: 18793847
[TBL] [Abstract][Full Text] [Related]
16. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
[TBL] [Abstract][Full Text] [Related]
17. Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.
Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Moskey MD; Pease LJ; Stewart KD; Yates M; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2006 Aug; 16(16):4326-30. PubMed ID: 16735117
[TBL] [Abstract][Full Text] [Related]
18. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.
Sessions EH; Yin Y; Bannister TD; Weiser A; Griffin E; Pocas J; Cameron MD; Ruiz C; Lin L; Schürer SC; Schröter T; LoGrasso P; Feng Y
Bioorg Med Chem Lett; 2008 Dec; 18(24):6390-3. PubMed ID: 18996009
[TBL] [Abstract][Full Text] [Related]
19. 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
Dinges J; Albert DH; Arnold LD; Ashworth KL; Akritopoulou-Zanze I; Bousquet PF; Bouska JJ; Cunha GA; Davidsen SK; Diaz GJ; Djuric SW; Gasiecki AF; Gintant GA; Gracias VJ; Harris CM; Houseman KA; Hutchins CW; Johnson EF; Li H; Marcotte PA; Martin RL; Michaelides MR; Nyein M; Sowin TJ; Su Z; Tapang PH; Xia Z; Zhang HQ
J Med Chem; 2007 May; 50(9):2011-29. PubMed ID: 17425296
[TBL] [Abstract][Full Text] [Related]
20. Novel inhibitor for fibroblast growth factor receptor tyrosine kinase.
Kammasud N; Boonyarat C; Tsunoda S; Sakurai H; Saiki I; Grierson DS; Vajragupta O
Bioorg Med Chem Lett; 2007 Sep; 17(17):4812-8. PubMed ID: 17618113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
